Biogen Plans Global Headquarters in Kendall Square

Biogen is planning to centralize its operations with a 580,000-sf global headquarters in the Kendall Common development in Cambridge, Mass. Representing a 15-year lease agreement, the facility’s strategic location will strengthen existing partnerships with MIT in research, education, and commercialization, and build on Biogen’s legacy as an integral part of the Kendall Square ecosystem. Designed by Elkus Manfredi Architects, 75 Broadway will provide mission-critical infrastructure to enable scientific excellence in bench-to-bedside clinical discovery. 

Highly advanced laboratories will be supported by state-of-the-art workspaces and modern amenities. With Biogen as the sole tenant, the purpose-built innovation hub aims to spark collaboration among employees and with external partners. Research and development teams will be integrated with the company’s global and North American commercialization operations under one roof. Additionally, a classroom-style community laboratory will offer job-training and career opportunities to drive talent generation in healthcare and the life sciences. Energy consumption and emissions will be reduced through the incorporation of advanced conservation, efficiency, and sustainable design measures.

BioMed Realty and MIT Investment Management Company are the joint-venture developers for the project, with John Moriarty & Associates as general contractor. Occupancy is slated for 2028.